Drug intelligence / Profile preview

GI-101 + pembrolizumab

Development stage: Unknown
Lead developer: GI Innovation
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

GI-101 + pembrolizumab is a combination therapy consisting of GI-101, a novel bispecific fusion protein containing CD80 and an interleukin-2 variant (IL-2v), and pembrolizumab, an anti-PD-1 monoclonal antibody. GI-101 is designed to boost immune cell proliferation including cytotoxic T and NK cells without increasing Treg cells, while pembrolizumab blocks the PD-1 pathway to help restore anti-tumor immune response. This combination aims to enhance anti-tumor activity through complementary immunotherapeutic mechanisms.

Targets

PDCD1 (Programmed cell death protein 1 receptor)CD28 (Cluster of Differentiation 28)CD274 (Programmed cell death protein 1 ligand 1)CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)

Beyond the preview

Go deeper on GI-101 + pembrolizumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GI-101 + pembrolizumab.

Explore the full profile